| Drug Name |
Levalbuterol hydrochloride |
| Drug ID |
BADD_D01263 |
| Description |
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
[Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). |
| Indications and Usage |
Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB13139
|
| KEGG ID |
D02281
|
| MeSH ID |
D064412
|
| PubChem ID |
123601
|
| TTD Drug ID |
D02ZJI
|
| NDC Product Code |
51927-5157; 17478-171; 17478-172; 35573-444; 35573-443; 17478-173; 76204-700; 15308-0310; 48954-719; 53104-7719; 17478-174; 17337-0524; 0115-9930; 35573-445; 0115-9932; 50090-6377; 76204-800; 76204-900; 0115-9931 |
| UNII |
WDQ1526QJM
|
| Synonyms |
Levalbuterol | Xopenex | Levalbuterol Hydrochloride | Hydrochloride, Levalbuterol | Levosalbutamol Hydrochloride | Hydrochloride, Levosalbutamol |
